Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Phase II Study in Patients With Metastatic Ocular Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes With or Without High Dose Aldesleukin
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Phase II Study in Patients With Metastatic Ocular Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes With or Without High Dose Aldesleukin
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Health Network
mi
from
Allentown, PA
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Utility of Novel BRAF Test for Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Utility of Novel BRAF Test for Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Utility of Novel BRAF Test for Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Utility of Novel BRAF Test for Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Utility of Novel BRAF Test for Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Utility of Novel BRAF Test for Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Alaska Breast Care and Surgery LLC
mi
from
Anchorage, AK
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Alaska Breast Care and Surgery LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Alaska Women's Cancer Care
mi
from
Anchorage, AK
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Alaska Women's Cancer Care
mi
from
Anchorage, AK
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Anchorage Oncology Centre
mi
from
Anchorage, AK
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Anchorage Oncology Centre
mi
from
Anchorage, AK
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Katmai Oncology Group
mi
from
Anchorage, AK
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Katmai Oncology Group
mi
from
Anchorage, AK
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Anaheim
mi
from
Anaheim, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Anaheim
mi
from
Anaheim, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Baldwin Park
mi
from
Baldwin Park, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Baldwin Park
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Harbor City
mi
from
Harbor City, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Harbor City
mi
from
Harbor City, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Irvine
mi
from
Irvine, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Los Angeles Medical Center
mi
from
Los Angeles, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Los Angeles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Cadillac
mi
from
Los Angeles, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Cadillac
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Palo Alto Medical Foundation Health Care
mi
from
Palo Alto, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Palo Alto Medical Foundation Health Care
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Panorama City
mi
from
Panorama City, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Panorama City
mi
from
Panorama City, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Riverside
mi
from
Riverside, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Diego Mission
mi
from
San Diego, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Diego Mission
mi
from
San Diego, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Diego Zion
mi
from
San Diego, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Diego Zion
mi
from
San Diego, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center-Mission Bay
mi
from
San Francisco, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center-Mission Bay
mi
from
San Francisco, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Marcos
mi
from
San Marcos, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Marcos
mi
from
San Marcos, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Palo Alto Medical Foundation-Santa Cruz
mi
from
Santa Cruz, CA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Palo Alto Medical Foundation-Santa Cruz
mi
from
Santa Cruz, CA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Medical Center of Aurora
mi
from
Aurora, CO
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Medical Center of Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Boulder Community Hospital
mi
from
Boulder, CO
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers - Boulder
mi
from
Boulder, CO
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Boulder
mi
from
Boulder, CO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers-Penrose
mi
from
Colorado Springs, CO
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Penrose
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Colorado Blood Cancer Institute
mi
from
Denver, CO
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Porter Adventist Hospital
mi
from
Denver, CO
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Click here to add this to my saved trials